Lipocine Profit Margin

The latest profit margin for LPCN is -571.1% as of March 2026. That compares with -146.13% in the prior-year period — down 290.8% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Lipocine's historical trend and sector peers before judging valuation or financial health.

Over the past year, LPCN's profit margin moved from -146.13% to -571.1% — a 290.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lipocine's valuation or profitability profile.

Against Healthcare companies, LPCN currently prints -571.1% for profit margin, while the sector average sits near 15.29%. That is roughly 3834.4% below the sector mean. Large gaps often invite a closer look at Lipocine's growth, margins, and balance sheet.

Profit Margin shows how effectively Lipocine converts resources into returns. At -571.1%, LPCN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -146.13% in the prior-year period — down 290.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LPCN's profit margin (-571.1%), review year-over-year change from -146.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.